Invivyd Shares Decline Following Delay in COVID-19 Therapy Trial Data

Key Facts

1Invivyd shares declined following the company's announcement of a delay in releasing late-stage trial data for its COVID-19 therapy.

Invivyd shares declined following the company's announcement of a delay in releasing late-stage trial data for its COVID-19 therapy. Reuters reported that the delay led to a negative market reaction, as postponements in clinical trial results often signal potential hurdles or extended timelines for regulatory approval.

IVVD closed at $0.95 on September 28, 2026, with the stock reaching a day high of $1.01 and a low of $0.94. This decline comes as biotech firms face pressure regarding the speed of delivering clinical research results to support market valuations.